Randomized controlled trial comparing letrozole with laparoscopic ovarian drilling in women with clomiphene citrate-resistant polycystic ovary syndrome
2015; Spandidos Publishing; Volume: 10; Issue: 4 Linguagem: Inglês
10.3892/etm.2015.2690
ISSN1792-1015
AutoresWei Liu, Shengnan Dong, Yumei Li, Lihong Shi, Wei Zhou, Yingling Liu, Jie Liu, Yazhong Ji,
Tópico(s)Ovarian cancer diagnosis and treatment
ResumoThe aim of the present study was to compare the reproductive outcomes of letrozole and laparoscopic ovarian drilling (LOD) in women with clomiphene citrate (CC)‑resistant polycystic ovary syndrome (PCOS). A total of 141 women with CC‑resistant PCOS were enrolled and randomly allocated into groups A and B. Group A (n=71) received 2.5 mg letrozole from days 5 to 10 of menses for up to six cycles, and group B (n=70) underwent LOD. A 6‑month follow‑up was performed. No statistically significant difference was found in the baseline clinical characteristics and the major serum hormone profiles, including luteinizing hormone, follicle‑stimulating hormone, estradiol and free testosterone, between the two groups. Women receiving letrozole had a lower rate of spontaneous abortion (6.9 vs. 15.8%) and higher clinical pregnancy (40.8 vs. 27.1%) and live birth (38.0 vs. 22.9%) rates; however, the differences were not statistically significant. Letrozole had superior reproductive outcomes compared with LOD in women with CC‑resistant PCOS; therefore, letrozole could be used as the first-line treatment for women with CC-resistant PCOS.
Referência(s)